Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.
2 min synopsisUK scopeSources checked 27 Aug 2026Clinical review pending
!
Organ-threatening metastatic complication
Spinal cord compression, symptomatic brain oedema, visceral crisis, hypercalcaemia, pulmonary embolism, major effusion, sepsis or fungating-tumour haemorrhage requires immediate physiological and anatomical rescue.
Action: Use ABCDE care and the relevant emergency pathway, give time-critical corticosteroid, anticoagulation, antibiotics, calcium treatment, drainage, radiotherapy or surgery as indicated and involve acute oncology and the breast team while tissue, receptor and systemic treatment planning proceeds in parallel.
Synopsis
Distinguish potentially curable locally advanced disease from stage IV cancer, rescue organ-threatening complications, re-establish tumour biology and sequence endocrine, targeted, cytotoxic, local and supportive treatment around patient goals.
Locally advanced M0 breast cancer remains potentially curable and usually receives systemic treatment first, followed by operability review, surgery and radiotherapy; stage IV disease is generally treated for durable control and quality of life.
Inflammatory breast cancer is a clinical pattern of rapid erythema and oedema from dermal lymphatic involvement and needs prompt core and often skin biopsy, systemic staging and multimodality treatment.
At metastatic diagnosis, biopsy an accessible lesion when feasible and repeat ER and HER2 because treatment targets can differ from the original primary.
Key red flags
New severe back pain, limb weakness, sensory change, gait disturbance or bladder or bowel dysfunction suggests metastatic spinal cord compression.
Brain or leptomeningeal disease
Headache, seizure, focal deficit, personality change, cranial neuropathy or radicular symptoms requires urgent contrast MRI and specialist review.
Investigation priorities
01
Preferred biopsy of accessible recurrenceFirst stepPreferred
Confirm metastatic breast cancer, exclude a second primary and reassess predictive receptors.
02
First-line contrast CT chest abdomen and pelvisFirst line
Map visceral, nodal, chest-wall and osseous disease and create a measurable response baseline.
Management branches
Locally advanced M0Downstage within a curative sequence
Breast, skin, chest-wall or regional nodal extent is advanced but distant staging remains negative.
Confirm histology and ER and HER2, clip tumour and positive nodes, complete systemic staging and assess inflammatory features, operability and baseline cardiac and functional status.
Give subtype-appropriate neoadjuvant systemic treatment and assess clinical response during therapy, escalating immediately for progression or threatened ulceration and bleeding.
Key medicines
Ribociclib with endocrine therapyGive ribociclib 600 mg orally once daily on days 1 to 21 of each 28-day cycle with the selected endocrine partner; reduce to 400 mg and then 200 mg for protocol-defined toxicity.
Trastuzumab deruxtecanGive trastuzumab deruxtecan 5.4 mg/kg by intravenous infusion every 3 weeks within the licensed and current NICE-funded breast-cancer indication, with dose interruption and reduction according to toxicity.
National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.